PowerShares Dynamic Pharmaceuticals PortfolioFind Ratings Reports
- Last Ratings Update:03/31/2017
- Price as of 03/31/2017 :$58.76
- Net Assets:$1,262.9 Million
- Peer Rank:27 of 35
- Investment Rating:D+
We rate PowerShares Dynamic Pharmaceuticals at D+. The fund invests approximately 100% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
POSITIVES AND RISKS
Total return ranks above peers over the last three years. The PowerShares Dynamic Pharmaceuticals has returned an annual rate of 14.01% since inception. More recently, the fund has generated a total return of 16.02% in the last five years, 5.28% in the last three years, and -3.25% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 94% of them. It has also outpaced 53% of its competitors on a three year basis and 11% of them over the last year for the period ending 3/31/2017. On a year to date basis, PJP has returned 4.94%.
Downside risk has been below average. PJP has a draw down risk of -31.44%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 18.8%. This fund has experienced a high level of volatility in its monthly performance over the last 36 months. As of 3/31/2017, the fund was trading at a price of $58.76, which is 3.6% below its 52-week high of $60.96 and 1.5% above its 52-week low of $57.89.
Low expense ratio helps performance. On total assets of $1.26 billion, PJP maintains a low expense ratio compared to its Sector - Health/Biotechnology peers of just 0.57% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As PJP is an exchange traded fund, it has no front end or back end load.
The PowerShares Dynamic Pharmaceuticals is managed by Peter Hubbard at Invesco Powershares Capital Mgmt LL. This fund is one of 130 Invesco Powershares Capital Mgmt LL exchange-traded funds launched since 5/1/2003 that we track.